News and events

ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first patient has been treated in a ...

September 1, 2021

ExeVir announces first subjects dosed Phase 1 clinical study of potent COVID-19 neutralizing antibody

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a ...

August 18, 2021

ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, and Mithra Pharmaceuticals (Euronext Brussels: MITRA) announce a new collaboration to ...

July 15, 2021

ExeVir’s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has generated data on its COVID-19 antibody ...

July 13, 2021

ExeVir Announces Close of $50 million/ EUR42 million Series A Financing

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising ...

March 16, 2021